Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 2/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL306297 | 1.00 | LMNA (0.57) | LMNATDP1TSHRTAAR1MEN1 | |
| SCHEMBL153049 | 1.00 | LMNA (0.57) | LMNATDP1TSHRTAAR1MEN1 | |
| Ammonia Solution, Strong SCHEMBL28849284 | 0.98 | LMNA (0.55) | LMNATDP1TSHRTAAR1MEN1 | |
| Water SCHEMBL8913477 | 0.98 | LMNA (0.55) | LMNATDP1TSHRTAAR1MEN1 | |
| SCHEMBL16993434 | 0.98 | LMNA (0.55) | LMNATDP1TSHRTAAR1MEN1 | |
| Methyl Alcohol SCHEMBL2110245 | 0.94 | LMNA (0.53) | LMNATDP1TSHRTAAR1MEN1 | |
| Methyl Alcohol SCHEMBL7344184 | 0.94 | LMNA (0.53) | LMNATDP1TSHRTAAR1MEN1 | |
| SCHEMBL471843 | 0.91 | TDP1 (0.50) | LMNATDP1TSHRTAAR1MEN1 | |
| SCHEMBL24932996 | 0.90 | LMNA (0.49) | LMNATDP1TSHRTAAR1MEN1 | |
| SCHEMBL8061754 | 0.90 | LMNA (0.49) | LMNATDP1TSHRTAAR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 682 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119120634-A | Process for the preparation of (R) -oxiranes based on epoxide hydrolases | 杭州微远生物科技有限公司 | 2024-12-13 | — | — | CN | claimed |
| CN-118978359-A | Temperature-inhibiting self-healing concrete anti-cracking waterproof agent and preparation method thereof | 山东鹏鑫建材科技有限公司 | 2024-11-19 | — | — | CN | claimed |
| CN-118147265-B | Chiral resolution method of oxirane compound based on epoxide hydrolase | 杭州微远生物科技有限公司 | 2024-11-05 | — | — | CN | claimed |
| CN-115948487-B | Method for preparing (R) -benzyl glycidyl ether by utilizing epoxide enzyme fusion and application thereof | 安徽工程大学 | 2024-06-21 | — | — | CN | claimed |
| CN-118147265-A | Chiral resolution method of oxirane compound based on epoxide hydrolase | 杭州微远生物科技有限公司 | 2024-06-07 | — | — | CN | claimed |
| CN-118028265-A | Epoxide hydrolase derived from streptomyces fei, gene, recombinant vector, engineering bacteria and application thereof | 安徽工程大学 | 2024-05-14 | — | — | CN | claimed |
| CN-117304464-A | Benzyloxy modified polymer and application thereof as oxygen scavenging material | 杭州碳氧力科技有限公司 | 2023-12-29 | — | — | CN | claimed |
| CN-117024473-A | Preparation method of L-alpha-phosphorylcholine | 沈阳金久奇科技有限公司 | 2023-11-10 | — | — | CN | claimed |
| CN-115948487-A | Method for preparing (R) -benzyl glycidyl ether by using epoxide enzyme fusion and application | 安徽工程大学 | 2023-04-11 | — | — | CN | claimed |
| CN-110423740-B | Halohydrin dehalogenase mutant for improving enantioselectivity and application thereof | 盐城工学院 | 2023-02-21 | — | — | CN | claimed |
| US-9284306-B2 | (R)-Nifuratel, its use for the treatment of infections and synthesis of (R) and (S)-Nifuratel | POLICHEM SA (LU) | 2016-03-15 | — | — | US | claimed |
| US-20150119431-A1 | (R)-Nifuratel, its use for the treatment of infections and synthesis of (R) and (S)-Nifuratel | POLICHEM SA (LU) | 2015-04-30 | — | — | US | claimed |
| EP-2847189-A1 | (R) -NIFURATEL, ITS USE FOR THE TREATMENT OF INFECTIONS AND SYNTHESIS OF (R) AND (S) -NIFURATEL | Polichem SA (LU) | 2015-03-18 | — | — | EP | claimed |
| WO-2013167295-A1 | (R) -NIFURATEL, ITS USE FOR THE TREATMENT OF INFECTIONS AND SYNTHESIS OF (R) AND (S) -NIFURATEL | POLICHEM SA (LU) | 2013-11-14 | — | — | WO | claimed |
| EP-2662371-A1 | (R)-Nifuratel and synthesis of (R) and (S)-Nifuratel | Polichem SA (LU) | 2013-11-13 | — | — | EP | claimed |
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | claimed |
| US-5608119-A | (2S)-3-[(1R, 2S, 5R)-[5-methyl-2-(1-methylethyl)-cyclohexyl]oxy]-1, 2-propanediol, process for producing the same, and compositions containing the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1997-03-04 | — | — | US | claimed |
| JP-3052879-A | — | — | None | — | — | JP | disclosed |
| JP-S624261-A | OPTICALLY ACTIVE SULFOXIDE COMPOUND | KAWAKEN FINE CHEM CO LTD | 1987-01-10 | — | — | JP | disclosed |
| JP-H00782200-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119431-A1 | (R)-Nifuratel, its use for the treatment of infections and synthesis of (R) and (S)-Nifuratel | BLVRB, NRDC, NISCH | LMNA 4327/4885TDP1 3435/4885TSHR 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.